Rocket Pharmaceuticals logo
Rocket Pharmaceuticals
RCKT | NASDAQ
Chart Builder DCF Calculator
$2.16
-$0.14 (-6.09%)
At close: Nov 16, 2026, 4:00 PM ET
$2.19
+$0.03 (+1.39%)
After-hours: Nov 16, 2026, 7:30 PM ET

Rocket Pharmaceuticals Company Profile

Company profile explained

Company Profile

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

Key Executives

Name Position
Gaurav D. Shah Chief Executive Officer & Director
Christopher Stevens Chief Operating Officer
Jonathan Schwartz Chief Science & Gene Therapy Officer
Joseph Manhede Principal Accounting Officer
Kevin Giordano Director of Corporate Communications
Martin Louis Wilson Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corporation Officer
Meg Dodge Senior Vice President & Head of External Affairs
Sarbani Chaudhuri Chief Commercial & Medical Affairs Officer
Syed Ali-Aamir Rizvi Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 06, 2026 8-K Current Report
Sep 15, 2026 4 Filing
Sep 15, 2026 8-K Current Report
Sep 02, 2026 25-NSE Filing
Aug 27, 2026 8-K Current Report
Aug 20, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
View All SEC Filings ➞
Rocket Pharmaceuticals
Rocket Pharmaceuticals logo
Country United States
IPO Date Feb 18, 2015
Industry Biotechnology
Sector Healthcare
Employees 202
CEO Gaurav D. Shah

Contact Details

9 Cedarbrook Drive Cranbury, New Jersey 08512 United States

Stock Details

Ticker Symbol RCKT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001281895
CUSIP Number 77313F106
ISIN Number US77313F1066
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.